21 research outputs found
Metastatic colorectal cancer in both sides of Aegean sea: practice patterns and outcome
Objective The successful results obtained in trials may not necessarily
translate into prolonged survival of metastatic colorectal cancer (mCRC)
patients in real life. This multinational registry study aimed to
evaluate the real-life data effecting the survival of patients with
mCRC. Methods This is a multinational, retrospective registry study.
Turkish and Greek mCRC patients diagnosed between 2005 and 2012, with at
least 3 years of follow-up data or who died before 3 years of follow-up
were included in the study. Results A total of 364 were included in the
study. RAS and BRAF mutation rates were found to be 36% and 39%,
respectively. As first-line therapy, 196 (54%) patients received
bevacizumab and Anti-EGFR treatments in combination with chemotherapy.
The objective response rate was 42% (n = 152) and 32% (n = 78) for
1(st) line and 2(nd) line treatments, respectively. While the median
progression-free survival (PFS) with the 1(st) line treatment was 10
months, it was 7 months with the 2(nd) line treatments. In the total
study population median PFS and overall survival (OS) were 10 (95% CI,
8.3-11.6) and 35 (95% CI, 30.7-39.2) months, respectively. In Turkish
and Greek patients, median OS (36 months versus 29 months, p = .81) and
PFS (10.2 versus 9.2, p = .42) were not different. In multivariate
analysis, ECOG PS of >= 2 and having metastases in more than one region
decreased overall survival (p = .002 and p = .003), it was found that
wild RAS and BRAF mutations and second metastasectomy contributed to
overall survival (p = .047 and p < .001). Conclusion In conclusion, it
seems that the patient’s performance status, tumor location, number of
metastatic lesions at the time of diagnosis affect the prognosis of
mCRC. Although access to molecular tests and first-line treatments
differ between Greece and Turkey, no significant difference was found in
survival times